Nakarin KitkumthornTime TuangsintanakulPrakasit RattanatanyongDanai TiwawechApiwat MutiranguraMahidol UniversityFaculty of Medicine, Chulalongkorn UniversityNational Cancer Institute Thailand2018-06-112018-06-112012-05-18Clinica Chimica Acta. Vol.413, No.9-10 (2012), 869-87418733492000989812-s2.0-84858614329https://repository.li.mahidol.ac.th/handle/20.500.14594/13729Background: Recently, we classified LINE-1 loci according to their methylation statuses and found that the percentage of hypomethylated LINE-1 loci ( u C u C) can differentiate between the peripheral blood mononuclear cells (PBMCs) of oral cancer patients and normal controls with a higher specificity and sensitivity than overall methylation levels. Here, we evaluated the LINE-1 methylation levels and patterns in PBMCs from patients with cancers of the nasopharynx, lung, liver, bile duct, breast and colon. Methods: Combined Bisulfite Restriction Analysis (COBRA) of LINE-1 loci was performed to examine the LINE-1 methylation statuses of PBMCs from 216 cancer patients with 6 different types of cancer compared with 144 normal controls. Results: Only colorectal and nasopharyngeal cancer samples were found to have lower levels of overall LINE-1 methylation compared with normal controls (p < 0.0001 and p=0.0022). However, % u C u C in cancers of the colon, liver, lung and nasopharynx was significantly higher compared with normal controls (p < 0.0001, p < 0.0001, p=0.01 and p=0.001, respectively). Furthermore, ROC curve analyses of these four cancer types also demonstrated the potential of % u C u C as a biomarker for cancer diagnosis. Conclusion: Changes in th e levels and patterns of genome-wide methylation of PBMCs are associated with cancer risk. For LINE-1, % u C u C is a more effective tumour marker for determining cancer risk than overall methylation levels. © 2012 Elsevier B.V.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/j.cca.2012.01.024